Indeed, the combination of Olaparib with a glutaminase inhibitor (CB-839) led to a six-fold decrease in the IC50 of the drug for a BRAC2-deficient high-grade serous ovarian cancers cell line, whereas monotherapy with CB-839 led to only slight sensitivity [228]. Here, GLS is linked to ovarian serous adenocarcinoma.